Dr. Reddy’s intros generic Xenazine
Dr. Reddy’s recently launched its generic Xenazine (tetrabenazine tablets). The product is indicated to treat chorea, or involuntary movements, of Huntington’s Disease.
Dr. Reddy’s generic Xenazine will be available in 12.5- and 25-mg dosage strengths. The product had a U.S. market size of roughly $322 million for the 12 months ended November 2017, according to IQVIA data.
The drug contains a boxed warning about its potential to increase the risk of depression and suicidality in patients.
Dr. Reddy’s generic Xenazine will be available in 12.5- and 25-mg dosage strengths. The product had a U.S. market size of roughly $322 million for the 12 months ended November 2017, according to IQVIA data.
The drug contains a boxed warning about its potential to increase the risk of depression and suicidality in patients.